My Crossword Maker Logo
Powered by BrightSprout
Save Status:
or to save your progress. The page will not refresh.
Controls:
SPACEBAR SWITCHES TYPING DIRECTION
Answer Key:
Edit a Copy:
Make Your Own:
Crucigrama Sopa de Letras Hoja de Trabajo
Calificar este Puzzle:
Log in or sign up to rate this puzzle.

The Cynical Scribe's Guide to the 20 Leading Suppliers of Infectious Disease Labs • ECCMID/ASM 2023 Edition

Looking for granular intelligence on cancer testing markets in Europe and the US? Contact [email protected] for a Zoom tour of our work.
Horizontales
In 2021 we were #11 in the US and #16 in Europe. Our covid revenues were down 36% in 2022 but our overall revenues were up 10% last year, after we bought a piece of Texas. Still our share price was down 20% in 2022.
In 2021 we were #17 in the US and #18 in Europe. We paid $137m+ last August for Curiosity Diagnostics and discussed matrimony with one of our digital PCR competitors in October. Our share price was down 43% in 2022.
In 2021 we were #14 in the US and #17 in Europe. But now liquid handling systems are cheap on eBay, so our AST systems are again our best foot forward in infectious disease testing.
In 2021 we were #6 in the US and #8 in Europe. Bacteriology and syndromic panels were both up 4-5% during 2022. But IA was down 15% and our share price was down 22% last year.
In 2021 we were #9 in both Europe and the US. Then in 2022 our diagnostic revenues were down 30% and we closed our Covid labs in California and England. Our share price was down 27% for the year.
In 2021 we were #2 in the US and #3 in Europe. Lazy news producers always show canned film of our boxes on TV, so our Covid revenues were actually up 9% during 2022. Still our share price was down 21% last year.
In 2021 we were #3 in the US and #10 in Europe. Our molecular diagnostic revenues were down 18% last year but our share price actually gained 2%.
During 2021 we were #20 in the US and #11 in Europe. Non-covid revenue was up 31% in 2022. Our new ultra-automated molecular system can do 37 syndromic tests, and will soon be tormenting bioMérieux, Roche, and Qiagen.
In 2021 we were #5 in the US and #1 in Europe. During 2022 our big molecular sales were down 15% while POC revenue was up 17%. Our share price was down 24% last year.
In 2021 we were #15 in the US and # 5 in Europe. Our total diagnostic revenues were up 12% during 2022, because our Covid antigen test was only FDA approved late in 2021. Still our share price was down 34% last year.
In 2021 we were #13 in Europe and not yet on the market in the US. Our OEM antigen kits brought Siemens nearly all of their 2022 growth in North America.
Verticales
In 2021 we were #8 in the US and #21 in Europe. We used our Covid money to acquire a company with about twice our revenues last year. Now we're #5 in clinical chemistry and #1 in blood bank serology. Our stock was down 36% last year.
In 2021 we were #7 in the US and #12 in Europe. Our Covid revenue went from $1,960m in 2021 to $511m in 2022. Still our share price was up 4% - better than any other on this puzzle.
During 2021 we were #19 in both the US and Europe. The swab and media business has seen better days, so now we focus on turning lab techs into Uber drivers with our WASP systems.
We were #6 in Europe and unranked in the US during 2021. We used some of our Covid windfall to buy Meridian last year. Antigen margins were OK for breakfast; but we want better margins for dinner.
In 2021 we were #10 in the US and scarce in Europe. During 2022 our Covid revenues were down 22% in our share price was down 84%. As the prophet Warren Buffet says: "When the tide goes out, we learn who's swimming naked."
In 2021 we were #4 in the US and #7 in Europe. Our Covid revenues were only down 1.5% last year. Humphrey Bogart once said "We'll always have Paris." Our sales managers always say "We'll always have MRSA."
In 2021 we were #1 in the US and #4 in Europe. During 2022 our Covid revenues were down 58% and our share price was down 15%.
In 2021 we were #12 in the US and #15 in Europe. Our diagnostics segment grew 3% during 2022. First it was Thermo, then it was Bio-Rad...every two years our staff gets spooked by M&A fears. Our share price was down just 8% last year - only two on this puzzle beat our modest decline.
In 2021 we were #14 in the US and #16 in Europe. Our diagnostic revenues were down 20% last year and our share price was down 27%. Fortunately our blood bank business grew by low double-digits in 2022.